Article
Genetic risk of prediabetes and diabetes development in chronic myeloid leukemia patients treated with nilotinib.
Experimental hematology - 1 Nov 2017
Martino Bruno, Mammì Corrado, Labate Claudia, Rodi Silvia, Ielo Domenica, Priolo Manuela, Postorino Maurizio, Tripepi Giovanni, Ronco Francesca, Laganà Carmelo, Musolino Caterina, Greco Marianna, La Nasa Giorgio, Caocci Giovanni
Abstract excerpt
Impaired fasting glucose and type 2 diabetes represent adverse events in patients with chronic myeloid leukemia (CML) treated with the second generation tyrosine kinase inhibitor nilotinib. An unweighted genetic risk score (uGRS) for the prediction of insulin resistance, consisting of 10 multiple single-nucleotide polymorphisms, has been proposed. We evaluated uGRS predictivity in 61 CML patients treated with...
Read the complete abstract on PubMedTopics
Share this publication in a Topic to start or enrich a Post.